About Careers Internship MedBlog Contact us

Dismissed Leukemia Drug Holds Cure For Treating Incurable Disease

by VR Sreeraman on December 9, 2008 at 3:33 PM
 Dismissed Leukemia Drug Holds Cure For Treating Incurable Disease

A drug previously found to be ineffective for chronic lymphocytic leukaemia (CLL) has now shown promising results in treating the incurable disease, say researchers.

The research team from The Ohio State University have devised a new dosing schedule for the drug to increase its anti-tumour activity and cure the potentially fatal disease.


The trials were conducted over 116 patients with advanced CLL, who were treated with the drug flavopiridol (alvocidib).

"Flavopiridol has bridged the way for several CLL patients to receive a curative stem cell transplant," said Dr. John Byrd, associate director of translational research and principal investigator of the phase II trial.

In the 1980s, animal tests showed flavopiridol to be a potent cancer-fighter.

But when researchers gave it to humans in repeated trials using a continuous prolonged infusion, the drug proved ineffective and was essentially forgotten.

The Ohio State researchers had later discovered that flavopiridol binds to proteins in human blood, which ties up much of the available drug and leaves less free drug in the bloodstream to kill cancer cells.

In essence, patients were not getting enough of the drug to be effective.

With the new dosing schedule, the researchers found that drug could effectively kill cancer cells.

"The new schedule increased the drug's blood level enough to kill cancer cells in humans, said Dr. Michael Grever, chairman of the department of internal medicine and co-leader of the Experimental Therapeutics program at Ohio State's Comprehensive Cancer Center.

The findings were presented at 50th Annual Meeting of the American Society of Hematology (ASH).

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

New Inverse Vaccine Sparks Hope in Diabetes, Arthritis, and Crohn's Disease
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Dismissed Leukemia Drug Holds Cure For Treating Incurable Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests